Skip to main content

Peer Review reports

From: Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study

Original Submission
9 Nov 2016 Submitted Original manuscript
8 Dec 2016 Author responded Author comments - Shenglong Ye
Resubmission - Version 2
8 Dec 2016 Submitted Manuscript version 2
2 Jan 2017 Reviewed Reviewer Report - Vijay Pandey
3 Jan 2017 Reviewed Reviewer Report - Renuka Iyer
6 Apr 2017 Author responded Author comments - Shenglong Ye
Resubmission - Version 3
6 Apr 2017 Submitted Manuscript version 3
19 Jun 2017 Author responded Author comments - Shenglong Ye
Resubmission - Version 4
19 Jun 2017 Submitted Manuscript version 4
11 Jul 2017 Author responded Author comments - Shenglong Ye
Resubmission - Version 5
11 Jul 2017 Submitted Manuscript version 5
9 Oct 2017 Author responded Author comments - Shenglong Ye
Resubmission - Version 6
9 Oct 2017 Submitted Manuscript version 6
8 Feb 2018 Author responded Author comments - Shenglong Ye
Resubmission - Version 7
8 Feb 2018 Submitted Manuscript version 7
Publishing
19 Feb 2018 Editorially accepted
2 Mar 2018 Article published 10.1186/s12885-018-4144-9

You can find further information about peer review here.

Back to article page